UGT Inhibitors
UDP-glucuronosyltransferases (UGTs) are a superfamily of Phase II metabolic enzymes responsible for the glucuronidation of a vast array of endogenous and exogenous compounds. This process involves the transfer of a glucuronic acid moiety from UDP-glucuronic acid to substrates containing functional groups such as hydroxyl, carboxyl, amino, or thiol groups, typically rendering them more water-soluble and easier to excrete via bile or urine. UGTs are primarily located in the endoplasmic reticulum of hepatocytes, but are also found in the kidneys, intestines, and other tissues. The UGT1A and UGT2B families are the most pharmacologically relevant. UGT inhibitors are molecules that block these enzymes, and they are studied for several reasons: to understand drug-drug interactions (DDIs), to modulate the pharmacokinetics of certain drugs, and to treat specific metabolic conditions. For example, UGT1A1 is the primary enzyme responsible for the conjugation of bilirubin; its inhibition can lead to hyperbilirubinemia, as seen in Gilbert’s syndrome or Crigler-Najjar syndrome.
In oncology, UGT1A1 also detoxifies SN-38, the active metabolite of irinotecan. Inhibiting UGT1A1 can lead to severe gastrointestinal toxicity and neutropenia due to the accumulation of SN-38. Conversely, some UGT inhibitors are used as research tools to prolong the half-life of drugs that are rapidly cleared by glucuronidation. Common inhibitors include probenecid, niflumic acid, and certain flavonoids like quercetin. Many drugs also act as unintended UGT inhibitors; for instance, the kinase inhibitors sorafenib and regorafenib are known to inhibit UGT1A1, which can lead to jaundice in patients. Inhibitors are classified by their selectivity (isoform-specific vs.
pan-UGT inhibitors) and their mechanism (competitive, non-competitive, or mechanism-based). A major challenge in this field is the high degree of structural homology between UGT isoforms, making the design of highly selective inhibitors difficult. Furthermore, because UGTs are involved in the clearance of many drugs, their inhibition carries a high risk of causing adverse drug reactions through metabolic interference. Current research is focusing on the development of selective UGT inhibitors to be used in 'humanized' animal models to better predict human drug metabolism. There is also interest in targeting UGTs that are overexpressed in certain cancers, where they contribute to drug resistance by rapidly inactivating chemotherapeutic agents. Understanding the structural biology of UGTs through homology modeling and X-ray crystallography is an ongoing effort to facilitate the rational design of more precise modulators of this critical metabolic pathway.
